What does CKPT's earnings trend suggest for future quarters?

Checkpoint Therapeutics' (CKPT) earnings trend suggests a challenging outlook for future quarters. The company's net income has been negative for the past three quarters, with a cumulative loss of $56.24 million by the end of 2024Q4. The estimated net income for 2025Q1 is -5.624 million, which is a 10% decrease from the previous quarter's net income. This indicates a continued decline in earnings and suggests that the company may face ongoing financial difficulties in the near term.

|code|Ticker|Name|Date|Net Income YoY|Net Income|market_code|
|---|---|---|---|---|---|---|
|CKPT|CKPT.O|Checkpoint|2022 Q1|-159.00076863950807|-1.6848E7|186|
|CKPT|CKPT.O|Checkpoint|2022 Q2|-54.65879265091863|-1.4142E7|186|
|CKPT|CKPT.O|Checkpoint|2022 Q3|5.796715490457168|-1.0612E7|186|
|CKPT|CKPT.O|Checkpoint|2022 Q4|29.35206344938836|-2.1022E7|186|
|CKPT|CKPT.O|Checkpoint|2023 Q1|37.832383665717|-1.0474E7|186|
|CKPT|CKPT.O|Checkpoint|2023 Q2|-16.822231650403054|-1.6521E7|186|
|CKPT|CKPT.O|Checkpoint|2023 Q3|46.06106294760649|-5724000|186|
|CKPT|CKPT.O|Checkpoint|2023 Q4|9.009608981067453|-1.9128E7|186|
|CKPT|CKPT.O|Checkpoint|2024 Q1|-4.496849341225893|-1.0945E7|186|
|CKPT|CKPT.O|Checkpoint|2024 Q2|59.62714121421221|-6670000|186|